Cargando…

How useful are biomarkers for the diagnosis of Alzheimer’s disease and especially for its therapy?

Detalles Bibliográficos
Autores principales:	Valenza, Marta, Scuderi, Caterina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9083181/ https://www.ncbi.nlm.nih.gov/pubmed/35259832 http://dx.doi.org/10.4103/1673-5374.335791

Ejemplares similares

Altered Waste Disposal System in Aging and Alzheimer’s Disease: Focus on Astrocytic Aquaporin-4
por: Valenza, Marta, et al.
Publicado: (2020)

Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
por: Valenza, Marta, et al.
Publicado: (2021)

Biomarker-guided drug therapy: personalized medicine for treating Alzheimer’s disease
por: Syal, Charvi, et al.
Publicado: (2021)

How mind-body therapies might reduce pathological features of Alzheimer’s disease
por: Hüttenrauch, Melanie, et al.
Publicado: (2022)

Astrocyte Function Is Affected by Aging and Not Alzheimer’s Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2019)

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease
por: Monteiro, Kadja Luana Chagas, et al.
Publicado: (2020)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer’s Disease
por: Facchinetti, Roberta, et al.
Publicado: (2022)

The viral hypothesis: how herpesviruses may contribute to Alzheimer’s disease
por: Wainberg, Michael, et al.
Publicado: (2021)

Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
por: Facchinetti, Roberta, et al.
Publicado: (2020)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on
por: Ledda, Caterina, et al.
Publicado: (2018)

Alzheimer's disease diagnosis and management: Perspectives from around the world
por: Kerwin, Diana, et al.
Publicado: (2022)

Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios
por: Bouwman, Femke H., et al.
Publicado: (2022)

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

Changes in electroencephalography and sleep architecture as potential electrical biomarkers for Alzheimer's disease
por: Yu, Hang, et al.
Publicado: (2021)

Biomarker discovery and beyond for diagnosis of bladder diseases
por: Jung, Sungyong, et al.
Publicado: (2020)

Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?
por: Corbo, Rosa Maria, et al.
Publicado: (2020)

Alzheimer’s and Consciousness: How Much Subjectivity Is Objective?
por: Bajic, Vladan, et al.
Publicado: (2021)

A Sense of Humor is Especially Important During Difficult Times
por: Mandelbaum, David E.
Publicado: (2021)

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022)

Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
por: Petersen, Ronald C., et al.
Publicado: (2023)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Antimicrobial Drug Resistance: "Prediction Is Very Difficult, Especially about the Future"
por: Courvalin, Patrice
Publicado: (2005)

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
por: Valenza, Marta, et al.
Publicado: (2022)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials
por: Gold, Michael, et al.
Publicado: (2018)

Hyperbaric oxygen therapy as a new treatment approach for Alzheimer’s disease
por: Shapira, Ronit, et al.
Publicado: (2018)

The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
por: Walgrave, Hannah, et al.
Publicado: (2021)

Direct oral anticoagulants: a new therapy against Alzheimer’s disease?
por: Grossmann, Klaus
Publicado: (2021)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

Targeting the Oxytocinergic System: A Possible Pharmacological Strategy for the Treatment of Inflammation Occurring in Different Chronic Diseases
por: Friuli, Marzia, et al.
Publicado: (2021)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
por: Souchet, Benoit, et al.
Publicado: (2018)

FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

How would preclinical Alzheimer’s disease (AD pathology) occur? An insight from a genomic instability mouse model
por: Rao, Chinthalapally V., et al.
Publicado: (2021)

Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders
por: Valenza, Marta, et al.
Publicado: (2021)

Newfound physiological function of FAIM protein offers hope of novel disease-modifying therapy for Alzheimer’s disease
por: Balaj, Allison R., et al.
Publicado: (2023)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0lo2ajorp9vkiak501hnbdn8ch